Medilabo

Kyoto, Japan· Est. 2020

Medilabo develops intranasal drug delivery technology to treat neurodegenerative diseases by directly targeting the brain via the olfactory nerve.

medilaborfp.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

Private Company

Estimated funding: $290M

AI Company Overview

Medilabo develops intranasal drug delivery technology to treat neurodegenerative diseases by directly targeting the brain via the olfactory nerve.

NeurologyPsychiatry

Technology Platform

Proprietary intranasal drug delivery platform that targets the olfactory region to enable direct nose-to-brain transport of small molecules, bypassing the blood-brain barrier and first-pass metabolism.

Opportunities

The company's platform enables repurposing of existing compounds with known safety profiles for CNS indications, potentially accelerating development timelines and reducing risk compared to novel drug discovery.

Risk Factors

As a preclinical company, Medilabo faces significant technical risks in translating their delivery technology to human efficacy and must compete in the highly challenging neurodegenerative disease therapeutic area.

Competitive Landscape

Medilabo competes with other nose-to-brain delivery companies like Impel NeuroPharma and Ikano Therapeutics, but differentiates through its specific focus on olfactory region targeting and repurposing of rifampicin/resveratrol for neurodegenerative diseases.

More companies in Japan →